Recombinant human melusin - Target Heart Biotec
Alternative Names: r-h melusinLatest Information Update: 06 Sep 2023
At a glance
- Originator Target Heart Biotec
- Class Antihypertensives; Heart failure therapies; Recombinant proteins
- Mechanism of Action Signal transduction pathway stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Cardiovascular disorders
Highest Development Phases
- Discontinued Heart failure
Most Recent Events
- 06 Sep 2023 Discontinued - Preclinical for Heart failure in Italy (unspecified route)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Heart-failure in Italy
- 06 Jul 2016 Recombinant human melusin is available for licensing as of 06 Jul 2016. http://www.thbiotec.com/